TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Merus(MRUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 32.7% and a total average return of -5.0%
Truist Financial Gives a Buy Rating to Merus (MRUS)
NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of Merus' Zenocutuzumab and Increased Adoption of NRG1 Fusion Biomarker Testing During the Study Period (2020-2034) | DelveInsight
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 40.4% and a
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and adjusts the target price from $48 to $100.According to TipRanks data, the analyst has a success rate of 40.4%
Buy Rating on Merus Backed by Strong Clinical Advantages and Market Positioning
Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
CCORF analyst John Newman maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $67.According to TipRanks data, the analyst has a success rate of 37.6% and a total average
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Express News | Merus NV : Citigroup Cuts Target Price to $89 From $93
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Brookdale Senior Living (BKD) and Arrowhead Pharmaceuticals (ARWR)
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Merus to Present at Canaccord Genuity's 44th Annual Growth Conference